Sun Pharma and Cipla recall U.S. drugs over manufacturing flaws, with low-to-moderate health risks.

Sun Pharma and Cipla have recalled several U.S. drugs due to manufacturing issues. Sun Pharma is recalling over 24,600 bottles of Fluocinolone Acetonide Topical Solution and certain Clindamycin Phosphate batches for failing impurity and degradation tests, both Class III recalls indicating low health risk. Cipla USA is recalling 15,221 Lanreotide Injection syringes due to particulate matter, a Class II recall with potential for temporary health effects. The recalls, initiated in late 2025 and early 2026, reflect ongoing FDA oversight of drug quality in the U.S. market.